In praise of povidone-iodine application in ophthalmology.

Conjunctivitis Endophthalmitis Eye Keratitis Ophthalmology Polyvinyl pyrrolidone Povidone-iodine

Journal

Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551

Informations de publication

Date de publication:
08 Nov 2023
Historique:
received: 28 07 2023
revised: 26 10 2023
accepted: 05 11 2023
pubmed: 10 11 2023
medline: 10 11 2023
entrez: 9 11 2023
Statut: aheadofprint

Résumé

Polyvinyl pyrrolidone or povidone-iodine (PVP-I) is a water-soluble complex formed by the combination of iodine and a water-soluble polymer, polyvinyl pyrrolidone. This complex exerts bactericidal, fungicidal, and virucidal action by gradually releasing free iodine at the site of application to react with pathogens. In ophthalmology, PVP-I is used as a disinfectant and antiseptic agent for preoperative preparation of the skin and mucous membranes and for treating contaminated wounds. PVP-I has been shown to reduce effectively the risk of endophthalmitis in various ocular procedures, including cataract surgery and intravitreal injections; however, it has also been used in the treatment of conjunctivitis, keratitis, and endophthalmitis, with promising results especially in low-resource situations. PVP-I has been associated with complications such as postoperative eye pain, persistent corneal epithelial defects, ocular inflammation, and an attendant risk of keratitis. In cases of poor PVP-I tolerance, applying PVP-I at lower concentrations or using alternative antiseptics such as chlorhexidine should be considered. We provide an update on the efficacy of PVP-I in the prophylaxis and treatment of conjunctivitis, keratitis, and endophthalmitis and a comprehensive analysis of the current literature regarding the use of PVP-I in the management of these ocular conditions. Also, PVP-I-related adverse effects and toxicities and its alternatives are discussed. The goal is to present a thorough evaluation of the available evidence and to offer practical recommendations for clinicians regarding the therapeutic usage of PVP-I in ophthalmology.

Identifiants

pubmed: 37944600
pii: S0039-6257(23)00143-1
doi: 10.1016/j.survophthal.2023.11.002
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Mohammad Soleimani (M)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran; Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: soleimani_md@yahoo.com.

Ali A Haydar (AA)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: ali.haydar01@lau.edu.

Kasra Cheraqpour (K)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: cheraqpourk@gmail.com.

Haniyeh Zeidabadinejad (H)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: hzeyd92@gmail.com.

Amirreza Esfandiari (A)

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: dramirreza1373@gmail.com.

Niloofarsadaat Eshaghhosseiny (N)

Harvard Medical University, MA, USA. Electronic address: waterliliniloo84@gmail.com.

Alireza Shahmohammadi (A)

Iran University of Medical Sciences, Tehran, Iran. Electronic address: alirezashmd@yahoo.com.

Soraya Banz (S)

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; University of Edinburgh, UK. Electronic address: soraya.banz@icloud.com.

Ali R Djalilian (AR)

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: adjalili@uic.edu.

Classifications MeSH